First International New Intravascular Rigid-Flex Endovascular Stent Study (FINESS): Clinical and Angiographic Results After Elective and Urgent Stent Implantation fn1fn1This study was supported in part by a grant from Medinol, Ltd., Kiryat Atidim, Tel Aviv, Israel.  by Almagor, Yaron et al.
CLINICAL STUDIES INTERVENTIONAL CARDIOLOGY
First International New Intravascular Rigid-Flex Endovascular Stent
Study (FINESS): Clinical and Angiographic Results After Elective and
Urgent Stent Implantation
YARON ALMAGOR, MD, STEVEN FELD, MD, FERDINAND KIEMENEIJ, MD, PHD,*
PATRICK W. SERRUYS, MD, PHD, FACC,† MARIE-CLAUDE MORICE, MD,‡
ANTONIO COLOMBO, MD, FACC,§ CARLOS MACAYA, MD, PHD,\ JEAN L. GUERMONPREZ, MD,¶
JEAN MARCO, MD,# RAIMUND ERBEL, MD, FACC,** IAN M. PENN, MD, FACC,††
RAOUL BONAN, MD, FACC,‡‡ MARTIN B. LEON, MD, FACC,§§ FOR THE FINESS
TRIAL INVESTIGATORS\ \
Jerusalem, Israel
Objectives. The purpose of this study was to determine the
feasibility, safety and efficacy of elective and urgent deployment of
the new intravascular rigid-flex (NIR) stent in patients with
coronary artery disease.
Background. Stent implantation has been shown to be effective
in the treatment of focal, new coronary stenoses and in restoring
coronary flow after coronary dissection and abrupt vessel closure.
However, currently available stents either lack flexibility, hinder-
ing navigation through tortuous arteries, or lack axial strength,
resulting in suboptimal scaffolding of the vessel. The unique
transforming multicellular design of the NIR stent appears to
provide both longitudinal flexibility and radial strength.
Methods. NIR stent implantation was attempted in 255 patients
(341 lesions) enrolled prospectively in a multicenter international
registry from December 1995 through March 1996. Nine-, 16- and
32-mm long NIR stents were manually crimped onto coronary
balloons and deployed in native coronary (94%) and saphenous
vein graft (6%) lesions. Seventy-four percent of patients under-
went elective stenting for primary or restenotic lesions, 21% for a
suboptimal angioplasty result and 5% for threatened or abrupt
vessel closure. Fifty-two percent of patients presented with unsta-
ble angina, 48% had a previous myocardial infarction, and 45%
had multivessel disease. Coronary lesions were frequently com-
plex, occurring in relatively small arteries (mean [6SD] reference
diameter 2.8 6 0.6 mm). Patients were followed up for 6 months
for the occurrence of major adverse cardiovascular events.
Results. Stent deployment was accomplished in 98% of lesions.
Mean minimal lumen diameter increased by 1.51 6 0.51 mm
(from 1.09 6 0.43 mm before to 2.60 6 0.50 mm after the
procedure). Mean percent diameter stenosis decreased from 61 6
13% before to 17 6 7% after intervention. A successful interven-
tional procedure with <50% diameter stenosis of all treatment
site lesions and no major adverse cardiac events within 30 days
occurred in 95% of patients. Event-free survival at 6 months was
82%. Ninety-four percent of surviving patients were either asymp-
tomatic or had mild stable angina at 6 month follow-up.
Conclusions. Despite unfavorable clinical and angiographic
characteristics of the majority of patients enrolled, the acute
angiographic results and early clinical outcome after NIR stent
deployment were very promising. A prospective, randomized trial
comparing the NIR stent with other currently available stents
appears warranted.
(J Am Coll Cardiol 1997;30:847–54)
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Improvements in operator technique and equipment have
enabled patients with unstable clinical syndromes, multivessel
disease and complex lesion morphology to undergo coronary
angioplasty or atherectomy with a high degree of procedural
success (1–5). Despite improvements in technology, such pa-
tients remain at increased risk for acute complications. Stent
implantation has proven to be a valuable asset to the interven-
tionalist in the setting of significant coronary dissection or
threatened or abrupt vessel closure (6–8). Coronary stenting
has also been shown to be an effective modality for reducing
the incidence of restenosis and clinical adverse events after
elective implantation in patients with new, discrete coronary
stenoses (9,10). Access to more difficult, longer lesions in tor-
From the Shaare Zedek Medical Center, Jerusalem, Israel; *Onze Lieve
Vrouwe Gasthuis, Amsterdam, The Netherlands; †Thoraxcenter, Rotterdam,
The Netherlands; ‡Institut Cardiovasculaire Paris Sud, Antony, France; §Centro
Cuore Columbus, Milan, Italy; \Hospital Universitario San Carlos, Madrid,
Spain; ¶Hoˆpital Broussais, Paris, France; #Clinique Pasteur, Toulouse, France;
**University Hospital, Essen, Germany; ††Vancouver Hospital, Vancouver,
British Columbia, Canada; ‡‡Institut de Cardiologie de Montreal, Montreal,
Quebec, Canada; and §§Washington Cardiology Center, Washington, D.C. \ \A
list of the participating institutions and investigators for the FINESS study
appears in the Appendix. This study was supported in part by a grant from
Medinol, Ltd., Kiryat Atidim, Tel Aviv, Israel.
Manuscript received March 3l, 1997; revised manuscript received June 26,
1997, accepted July 1, 1997.
Address for correspondence: Dr. Yaron Almagor, Cardiac Catheterization
Laboratory, Shaare Zedek Medical Center, P.O. Box 3235, Jerusalem 91031,
Israel. E-mail: cardio@szmc.org.il.
JACC Vol. 30, No. 4
October 1997:847–54
847
©1997 by the American College of Cardiology 0735-1097/97/$17.00
Published by Elsevier Science Inc. PII S0735-1097(97)00269-6
tuous vessels and preservation of arterial contour will necessi-
tate improvements in stent design. A number of second-
generation stents have recently been introduced with
encouraging early results (11,12). The new intravascular rigid-
flex (NIR) stent was designed specifically to provide greater
longitudinal flexibility and trackability during deployment,
while maintaining high radial support and stent conformation
to the vessel wall after implantation. These geometric consid-
erations may be of particular importance in patients with
complex lesions. We report the initial results of a multicenter,
prospective, observational study with the NIR stent, including
procedural success and 6-month clinical follow-up.
Methods
Patient selection. Patients with objective evidence of myo-
cardial ischemia scheduled to undergo balloon angioplasty of
native coronary arteries or saphenous vein bypass grafts were
eligible for inclusion in the study. The target lesion needed to
be ,32 mm in length to permit a single NIR stent to
completely cover the lesion and be located in a vessel whose
reference diameter on visual inspection or quantitative arte-
riography was $3.0 and #5.0 mm in diameter. Patients with
unprotected left main coronary artery disease, bifurcation
lesions, degenerated saphenous vein grafts, suspected intralu-
minal thrombus, heavily calcified lesions that would preclude
adequate predilatation, recent myocardial infarction (within
72 h) and severe left ventricular dysfunction (ejection fraction
,30%) were excluded. Patients with leukopenia, neutropenia
or thrombocytopenia, active peptic ulcer disease or gastroin-
testinal bleeding in the previous 6 months or an intolerance to
therapy with aspirin or ticlopidine were also excluded.
The study was conducted according to the principles of the
Declaration of Helsinki, and written informed consent was
obtained for all patients.
Stent procedure. Coronary angiography and intervention
were performed according to standard clinical practice by the
femoral or radial approach. Patients received aspirin
($100 mg/day) and ticlopidine (250 mg twice daily) beginning
the day before elective stent implantation. Ticlopidine was
given at the time of catheterization in patients who did not
receive the medication on the day before the interventional
procedure. During coronary intervention, patients received an
initial intravenous bolus of heparin (10,000 U) supplemented
as needed to maintain an activated clotting time .300 s. For
elective stent deployment, predilation of the target lesion was
performed using a balloon of appropriate length that was
either undersized or equivalent in size to the reference vessel
diameter determined by visual assessment or on-line quantita-
tive coronary angiography. Predilation was considered satisfac-
tory when a sufficient lumen caliber for subsequent unimpeded
stent deployment across the lesion site was achieved. A
nine-cell NIR stent of sufficient length (9, 16 or 32 mm) to
cover the entire lesion and correct diameter, yielding a stent to
distal reference diameter ratio #1.1:1, was chosen. The NIR
stent was manually crimped onto an appropriately sized coro-
nary balloon after removal of the balloon’s lubricious coating
with an organic solvent. The 9-mm NIR stent was mounted on
a 10-mm balloon, the 16-mm NIR stent on a 20-mm balloon
and the 32-mm NIR stent on a 36-mm balloon. Intracoronary
nitroglycerin (0.2 mg) was administered before and after stent
implantation. Stents were deployed at 2 to 4 atm above
nominal balloon inflation pressure. After stent deployment,
moderately high pressure balloon inflation of 12 to 16 atm with
semicompliant or noncompliant coronary balloons was then
performed. Angiographic criteria for optimal stent expansion
were achieved when the diameter stenosis within the stent was
,20% and the mean diameter of the stent was greater than or
equal to the reference diameter of the vessel. If the angio-
graphic appearance of the target lesion was suboptimal, inves-
tigators were permitted to use further balloon inflation or
additional stent deployment with or without intravascular
ultrasound guidance, as deemed necessary. Heparin was dis-
continued on completion of the procedure, and vascular
sheaths were removed the same day, according to institutional
practice. Patients were treated with ticlopidine (250 mg twice
daily for 1 month) and aspirin ($100 mg/day for at least 6
months). Warfarin sodium (Coumadin) was prescribed at
operator discretion on the basis of an unsatisfactory proce-
dural result.
Follow-up and clinical end points. Clinical evaluation was
performed before hospital discharge and at 30 days and 6
months after stent implantation. A complete blood count,
including differential white blood cell and platelet counts were
obtained every 2 weeks while the patient was treated with
ticlopidine. A prothrombin time and international normalized
ratio were obtained once or twice weekly for patients receiving
warfarin. The primary clinical end point was the occurrence of
a major adverse cardiac event (death, myocardial infarction or
target lesion revascularization) or bleeding or vascular compli-
cation necessitating transfusion or operation within 30 days of
stent implantation. Myocardial infarction was diagnosed when
two of the following criteria were met: 1) a history of chest
discomfort of at least 30 min in duration; 2) development of
new abnormal Q waves of at least 0.04 s in duration; and 3)
enzyme elevation of creatine kinase and CK-MB fraction
(when available) to more than twice the upper limit of normal.
A secondary clinical end point was the occurrence of a major
adverse cardiac event, significant bleeding or vascular compli-
cation, as previously described, within 6 months of the proce-
dure. Independent monitors were dispatched to each investi-
gational site to ensure the quality of clinical data.
Angiographic analysis and end points. Coronary angiogra-
phy was performed in at least two orthogonal projections
chosen to optimally assess lesion site morphology. Identical
views were obtained before and after coronary intervention
after intracoronary administration of nitroglycerin (0.2 mg).
All angiograms were sent to the core laboratory (Cardialysis,
Rotterdam, The Netherlands) and analyzed by the Cardiovas-
cular Angiography Analysis System. Guidelines to ensure
uniform, reproducible data acquisition during angiography of
coronary segments before and after intervention have been
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described elsewhere (13). Selected end-diastolic cine frames
were digitized for off-line quantitative arteriographic analysis.
Vessel size, lesion length, minimal lumen diameter and percent
diameter stenosis were determined from a computer-generated
interpolated reference diameter by using previously validated
software for image processing that involves edge detection,
contour reconstruction, magnification and pincushion correc-
tion and morphologic analysis of the stenosis (14). The primary
angiographic end point was the acute gain in minimal lumen
diameter of the target vessel stenosis after stent implantation.
A secondary end point was initial angiographic success result-
ing in a reduction in percent diameter stenosis to ,50% of the
reference diameter of the stented segment measured by off-
line quantitative coronary angiography.
Statistical analysis. Results are expressed as mean value 6
SD. The unpaired two-tailed Student t test was performed for
comparative analysis of continuous variables. A p value ,0.05
was considered significant.
Results
Baseline characteristics. A total of 255 patients were en-
rolled at 11 clinical centers from December 1995 through
March 1996. All patients were included in the clinical analysis,
although many patients did not meet strict angiographic en-
rollment criteria (stent implantation in small vessels or across
significant side branches), which may have influenced out-
come. In addition, three patients underwent uncomplicated
primary stent implantation in the setting of an acute myocar-
dial infarction. NIR stent implantation was not accomplished
in six patients because of inability to dilate the lesion (one
patient) and failure to cross the lesion with the NIR stent (five
patients). Of these six patients, two were treated with another
stent design, and four underwent conventional balloon angio-
plasty. An additional 10 patients had poor quality imaging or
tape loss or damage that precluded quantitative measure-
ments. Quantitative angiographic analysis was available in 239
of the 255 enrolled patients and in 306 of 335 stented lesions.
The baseline clinical and angiographic characteristics are
shown in Tables 1 and 2. Overall, the study group represented
a high risk cohort. More than half of the patients (52%)
presented with unstable angina, 48% had a previous myocar-
dial infarction, and 45% had multivessel coronary artery
disease. Nonelective stent implantation was performed in 26%
of patients for either abrupt or threatened vessel closure or for
a suboptimal angiographic result. Among patients who under-
went elective stent implantation, 20% were deployed in rest-
enotic lesions. Seventy percent of stented lesions were either
B2 or C lesions according to the American Heart Association/
American College of Cardiology classification (18). Reference
diameter of the target vessel before intervention determined
by off-line quantitative coronary arteriography performed at
the core laboratory was ,2.75 mm in 48% of stented lesions
and ,2.5 mm in 31%. Although only 6% of lesions were
assessed to be .15 mm in length by quantitative angiography,
experienced operators chose a long (32 mm) NIR stent for
26% of the NIR stents that were deployed. This choice may
reflect a desire by the interventionalist to more completely
cover visible vessel narrowing beyond the area of significant
stenosis or to treat consecutive lesions with a single stent. The
relatively high incidence (26%) of stent deployment for abrupt
closure, dissection or suboptimal result in our series of patients
may have also contributed to the use of longer stents for
initially discrete stenoses.
Procedural outcome. Procedural characteristics and out-
comes are shown in Table 3. Twenty-three percent of patients
had more than one lesion stented and 47% had more than one
stent implanted; 26% of stents used were 32 mm in length.
NIR stents were deployed in 335 (98.2%) of 341 lesions
attempted. Stent deployment was considered angiographically
successful when the percent diameter stenosis assessed by
averaging multiple matched views on quantitative coronary
angiography performed at the core laboratory was ,50% of
the reference vessel diameter after stenting. Angiographic
success was achieved in 100% of stented lesions. A percent
diameter stenosis ,20% was achieved in 68% of stented
lesions. The intervention was considered successful when the
percent diameter stenosis of the stented lesion was ,50% of
the reference diameter (angiographic success) in the absence
of major bleeding or adverse cardiac events during the hospital
Table 1. Baseline Clinical Characteristics of 255 Study Patients
Age (yr) 61 6 10
Male 215 (84%)
Diabetes 39 (15%)
Insulin treated 7 (3%)
Hypertension 115 (45%)
Hypercholesterolemia 144 (56%)
Family history 89 (35%)
Prior MI 121 (48%)
Prior angioplasty 83 (33%)
Prior CABG 36 (14%)
Prior stroke 6 (2%)
Peripheral vascular disease 18 (7%)
Multivessel disease 115 (45%)
Anginal status
Unstable* 133 (52%)
Crescendo (IB) 45 (18%)
Rest (IIB, IIIB) 65 (25%)
Postinfarction (IC, IIC, IIIC) 23 (9%)
Stable† 96 (38%)
Class I 15 (6%)
Class II 42 (16%)
Class III 38 (15%)
Class IV 1 (,1%)
Silent ischemia 26 (10%)
Stent indication
Primary lesion 162 (59%)
Restenotic lesion 40 (15%)
Suboptimal result 57 (21%)
Abrupt/threatened closure 14 (5%)
*Braunwald classification (15). †Canadian Cardiovascular Society classifica-
tion (16). Data presented are mean value 6 SD or number (%) of patients.
CABG 5 coronary artery bypass graft surgery; MI 5 myocardial infarction.
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period. Procedural success was achieved in 95% of 306 stented
lesions and in 95% of 255 patients on an intention to treat
basis. Quantitative and qualitative angiographic results appear
in Table 4. Acute gain in minimal lumen diameter of stented
lesions averaged 1.51 6 0.51 mm, accompanied by a significant
reduction in average percent diameter stenosis from 61 6 13%
to 17 6 7% after intervention. Mean maximal balloon inflation
pressure for stent expansion was 15.6 6 3.3 atm (range 4.0 to
24.0).
Clinical events. Twelve patients had major adverse cardiac
events in the first month after NIR stent implantation (Table
5). Three patients with multivessel coronary artery disease died
during the hospital period or within 1 month of successful NIR
stent implantation. The first patient underwent successful NIR
stent implantation for lesions in the right coronary, circumflex
and obtuse marginal coronary arteries but subsequently died of
a massive anterior wall myocardial infarction due to proximal
left anterior descending coronary artery occlusion. All stented
arteries were patent on angiography performed immediately
before death. The second patient with severely compromised
left ventricular function and four previous myocardial infarc-
tions had an NIR stent deployed across a bifurcation lesion in
a saphenous vein jump bypass graft that supplied the obtuse
marginal branch of the circumflex artery and the right poste-
rior descending artery. Major side branch (obtuse marginal)
occlusion occurred after stent deployment, ultimately leading
to the patient’s death. The third patient underwent successful
deployment of two NIR stents for two lesions in the left
Table 2. Baseline Angiographic Characteristics*
No. of lesions stented 306
No. of lesions stented/patient (mean) 1.3
1 185 (77%)
2 42 (18%)
3 11 (5%)
4 1 (,1%)
Vessel size (mm) 2.83 6 0.61
Range 1.64–6.11
Lesion length (mm) 8.68 6 3.69
Range 1.91–30.84
MLD (mm) 1.09 6 0.43
Range 0.0–3.02
% diameter stenosis 61 6 13
Range 25–100
Target lesion vessel
LAD 107 (35%)
LCx 69 (23%)
RCA 108 (35%)
LMCA 3 (1%)
SVG 19 (6%)
Lesion characteristics†
Concentric 13 (4%)
Eccentric type IA 105 (34%)
Eccentric type IB 112 (37%)
Eccentric type IIA 4 (1%)
Eccentric type IIB 3 (1%)
Multiple irregularities 48 (16%)
Tandem lesion 9 (3%)
Total occlusion 12 (4%)
Lesion classification‡
Type A 6 (2%)
Type B1 86 (28%)
Type B2 197 (64%)
Type C 17 (6%)
Calcification 84 (27%)
*Based on 239 patients with adequate qualitative and quantitative angio-
graphic analysis. †Ambrose score (17). ‡American Heart Association/American
College of Cardiology classification (18). Data presented are mean value 6 SD
or number (%) of patients, unless otherwise indicated. LAD 5 left anterior
descending coronary artery; LCx 5 left circumflex coronary artery; LMCA 5 left
main coronary artery; MLD 5 minimal lumen diameter; RCA 5 right coronary
artery; SVG 5 saphenous vein graft.
Table 3. Procedural Characteristics and Outcome
Stent inventory
No. of stents used 457
9 mm 66 (14.4%)
16 mm 272 (59.5%)
32 mm 119 (26.0%)
No. of stents/patient (mean) 1.8
0 6 (2.4%)
1 128 (50.2%)
2 74 (29%)
3 29 (11.4%)
.3 18 (7.1%)
Procedural outcome*
Angiographic success
% DS ,20% 207 (67.6%)
% DS ,50% 306 (100%)
Procedural success†
% DS ,20% 196 (64.1%)
% DS ,50% 290 (94.8%)
*Procedural outcome for 306 stented lesions with adequate quantitative
angiographic analysis. †Angiographic success of all lesions with no major adverse
cardiovascular events during the hospital period. Data presented are number
(%) of patients, unless otherwise indicated. % DS 5 percent diameter stenosis.
Table 4. Quantitative and Qualitative Angiographic Results
No. of lesions 306
Ref vessel diameter (mm)
Before procedure 2.83 6 0.61
After procedure 3.15 6 0.51*
MLD (mm)
Before procedure 1.09 6 0.43
After procedure 2.60 6 0.50†
Acute gain (mm) 1.51 6 0.51
% DS (%)
Before procedure 61 6 13
After procedure 17 6 7†
Dissection‡
Type A 19 (6.2%)
Type B 25 (8.2%)
Type C 2 (,1%)
Thrombus 1 (,1%)
*p , 0.05, before versus after procedure. †p , 0.001, before versus after
procedure. ‡National Heart, Lung, and Blood Institute classification for coro-
nary dissection (19). Data presented are mean value 6 SD or number (%) of
patients, unless otherwise indicated. Abbreviations as in Tables 2 and 3.
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anterior descending artery. Elective angioplasty of a circumflex
stenosis was performed in a subsequent procedure, resulting in
significant dissection. NIR and Palmaz-Schatz stent deploy-
ment was complicated by proximal dissection into the left main
coronary artery and cardiovascular collapse. The patient died
after emergency coronary artery bypass graft surgery. An
additional eight patients experienced an acute myocardial
infarction within 1 month of NIR stent implantation. In three
of four patients with Q wave infarctions, myocardial infarction
appeared to be the result of side branch occlusion (two
patients) and distal embolization during bypass graft interven-
tion of a nonstented artery (one patient). There were no cases
of suspected acute or subacute stent thrombosis. Creatine
kinase and CK-MB fraction were measured after intervention
in 91.4% and 38.4% of patients, respectively. Elective surgical
revascularization was performed in two patients with a non-Q
wave myocardial infarction that followed multivessel interven-
tion, including NIR stent implantation. In both patients, the
stented arteries were patent. Emergency bypass surgery was
performed in two patients, one of whom died during the
hospital period (described earlier). The second patient had two
successful NIR stents implanted in the right coronary artery
but required urgent surgical intervention after perforation of
an occluded left anterior descending coronary artery during
attempted angioplasty.
Complete 6-month clinical follow-up was obtained in 243
(98.4%) of 247 surviving patients and is summarized in Table
5. A total of 60 adverse cardiac events were encountered in 47
(18.4%) of enrolled patients after coronary intervention. Hi-
erarchic ranking of all clinical events revealed that eight
patients died, 10 experienced a myocardial infarction, and the
remaining 29 underwent repeat percutaneous or surgical re-
vascularization of the target vessel. Ninety-four percent of
surviving patients were either asymptomatic or had mild stable
angina (Canadian Cardiovascular Society class I or II) at their
6-month follow-up visit.
Discussion
Mechanical properties of NIR stent. The NIR stent is a
tubular patterned multicellular stainless steel stent available in
9-, 16-, 25- and 32-mm lengths (Fig. 1). The NIR stent is
manually crimped onto an appropriately sized balloon that is
equal to or slightly larger than the normal reference vessel
diameter during high pressure inflation. The expanded diam-
eter of the NIR stent is between 2 and 5 mm. NIR stents
containing seven attached cells in circumference are appropri-
ate for implantation in smaller diameter vessels (2 to 3.5 mm),
whereas the nine-cell NIR stents are recommended for opti-
mal structural support and expansion of larger (3.5 to 5.0 mm)
arteries. When the NIR stent is expanded to 3 mm, the cell
diameter of the seven-cell NIR stent is double that of the
nine-cell NIR stent (1.2 vs. 0.6 mm), permitting better access to
side branches covered by a seven-cell NIR stent. Only nine-cell
NIR stents were used in the present trial. The NIR stent is a
highly flexible stent with excellent trackability. Most of the
struts of the unexpanded NIR stent parallel the insertion
direction, without free flare points, permitting unimpeded
stent delivery through tortuous, atheromatous vessels to the
site of implantation. Once deployed, the NIR stent transforms
into a diamond-like mesh of uniform cellular design that
provides rigid scaffolding of the vessel wall. Stent expansion
results in alignment of horizontal struts that forshorten, with
vertical loops that elongate such that the overall stent length is
preserved. There are no articulation sites or gaps in the NIR
stent, which minimizes tissue prolapse. The cellular structure
of the NIR stent was designed to provide differential elonga-
tion of the struts (Fig. 2). This unique feature not only
facilitates delivery of the unexpanded stent to the lesion site,
but also favors stent conformity with the vessel curvature after
deployment with minimal deformation of the vessel.
Clinical results. We describe a multicenter experience with
this novel balloon-expandable, “transformable” multicellular
stent, including initial angiographic results and 6-month clini-
cal follow-up. Stents were deployed in frequently complex
lesions (only 2% were classified as type A lesions) occurring in
native coronary arteries and saphenous vein grafts. Six-month
angiographic evaluation after NIR stent deployment in more
uniform lesions that would meet inclusion criteria for enroll-
ment in the Stent Restenosis Study (STRESS) (10) or the
Belgium-Netherlands Stent Trial (BENESTENT) (9) will be
the subject of a second international trial now in progress.
Studies involving serial quantitative angiographic and intra-
coronary ultrasound measurements have provided predictable
Table 5. Major Adverse Cardiovascular Events and Clinical Follow-Up
Adverse Events
0–30 Days 0–180 Days
No. of pts followed up 255 255
No. of pts with cardiac events 12 (4.7%) 47 (18.4%)
Total cardiac events 18 (7.1%) 60 (23.5%)
Death 3 (1.2%) 8 (3.1%)
MI 11 (4.3%) 15 (5.8%)
Q wave 5 (2.0%) 7 (2.7%)
Non-Q wave 6 (2.4%) 8 (3.1%)
Perc revasc of target vessel 0 24 (9.4%)
CABG 4 (1.6%) 13 (5.1%)
Urgent 2 (0.8%) 2 (0.8%)
Elective 2 (0.8%) 11 (4.3%)
Major bleeding 3 (1.2%) 3 (1.2%)
Anginal status
No. of pts followed up 238 243
No angina 205 (86.1%) 184 (75.7%)
Unstable angina 0 5 (2.1%)
Stable angina* 32 (13.4%) 47 (19.3%)
Class I 14 (5.9%) 9 (3.7%)
Class II 14 (5.9%) 29 (11.9%)
Class III 4 (1.6%) 8 (3.3%)
Class IV 0 1 (0.4%)
Silent ischemia 1 (0.4%) 7 (2.9%)
*Canadian Cardiovascular Society classification (16). Data presented are
number (%) of patients (pts), unless otherwise indicated. Perc revasc 5
percutaneous revascularization; other abbreviations as in Table 1.
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relations between “acute gain” after balloon angioplasty or
newer device intervention and “late loss” in lumen diameter
(20). Furthermore, an improvement in minimal lumen diame-
ter on angiographic follow-up does not necessarily translate
into improvement in clinical outcome (21). The combination of
acute angiographic results and clinical follow-up for major
adverse cardiovascular events should provide a reliable means
for determining NIR stent performance and the biologic
response of the target lesion to intervention (22,23). A pilot
study that involved NIR stent implantation for 64 lesions in 41
consecutive patients reported successful deployment in 97% of
lesions and no acute or subacute thrombosis. Unfavorable
coronary anatomy or lesion characteristics that may reduce
procedural success, such as severe proximal vessel tortuosity,
long lesion length (.15 mm) or small-caliber vessels (,2.5 mm
diameter) were present in nearly half of the lesions stented
(24).
In the present trial, immediate angiographic and procedural
success with NIR stent implantation was impressive despite the
inclusion of patients with unfavorable clinical or angiographic
characteristics that increase the risk of coronary intervention
(25,26). Stent deployment was accomplished in 98% of lesions
attempted. Stenoses were often complex (70% were type B2 or
C), requiring long (32 mm) or multiple stents in 26% and 47%
of lesions, respectively. Patients with distal stenoses in tortuous
vessels were not excluded. Procedural success was achieved in
95% of stented lesions. The definition of procedural success
was similar to that used in previous randomized stent trials
(9,10), consisting of ,50% residual diameter stenosis after
stent deployment in the absence of in-hospital cardiovascular
complications.
Residual stenosis after NIR stent implantation was 17% on
quantitative analysis. High risk clinical characteristics of the
study group included unstable coronary syndromes (52%),
multivessel disease (44%) and unplanned stent deployment
(26%). Moreover, all patients enrolled in the present trial were
included in the statistical analysis, even though some develop-
ing complications did not meet entry criteria. This included
patients with acute myocardial infarction, severe left ventricu-
lar dysfunction and bifurcation lesions involving major side
branches. By comparison, Palmaz-Schatz stent deployment was
achieved in 94% and 98% of patients with relatively uncom-
plicated lesions enrolled in the BENESTENT and STRESS
trials, with procedural success rates of 93% and 96%, respec-
tively. Postprocedural diameter stenosis was 19% and 22% for
patients with stented lesions in the STRESS and BENEST-
ENT trials, respectively, and 18% in Phase 4 of the BENEST-
ENT II trial (27), where high pressure inflation was routinely
used in an attempt to optimize stent expansion.
Major early adverse clinical events encountered in the
present trial were few, usually occurring in patients with
multivessel disease, and frequently unrelated to the procedure
involving NIR stent implantation. Eighteen major adverse
cardiac events occurred within 1 month of NIR stent implan-
tation in 12 patients (4.7%). This rate compares favorably to
the early cardiac event rate encountered in the patients with
stent placement enrolled in the STRESS and BENESTENT
trials (5.9% and 6.9% of patients, respectively). In these two
Figure 1. A, Crimped stent shows uniform cellular
pattern, each cell containing vertical loops that allow
flexibility during insertion. B, Expanded stent shows
uniform cellular design, with expanded cells having
aligned struts constituting the rigidity of the stent
after expansion.
Figure 2. A, Crimped stent is flexible by virtue of
differential elongation of vertical loops (note the
difference in opening of the vertical loop inside [1]
and outside [2] the curve). B, Stent expanded in a
curve shows conformity to curvature by the same
differential elongation (note the difference in length
of the loop inside [1] and outside [2] the curve).
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randomized trials, there was no in-hospital death in patients
assigned to receive a Palmaz-Schatz stent for new, single,
discrete, native coronary artery lesions. Three deaths occurred
within 1 month of NIR stent implantation in the present trial,
yielding a 1.2% early mortality rate. All fatal events followed
multivessel intervention for complex lesions in clinically high
risk patients. Five additional patients died during follow-up.
During the 6 months after coronary intervention, a total of
eight patients (3.1%) died, and 18.4% of enrolled patients
experienced an adverse cardiac event. The need for repeat
target lesion revascularization comprised the majority of late
adverse events. Event-free survival 6 months after NIR stent
implantation was 81.6% compared with 79.9% in the BE-
NESTENT study and 80.5% in the STRESS trial at 7 and 8
months, respectively.
Limitations of the study. Although nearly 25% of the
patients enrolled in the present trial had some degree of
angina or silent ischemia during follow-up, restenosis after
NIR stent implantation is difficult to estimate on clinical
grounds because almost 50% of the patients had multivessel
disease. Coronary arteriography was not routinely performed
in patients at the time of 6-month follow-up and would have
provided important information concerning the incidence of
in-stent stenosis.
The acute angiographic results obtained after NIR stent
implantation are comparable to those of other stent trials
conducted before and after postdeployment high pressure
balloon inflation became commonly used (9,10,27). Nonethe-
less, nearly one-third of patients (32%) had a residual stenosis
.20% after high pressure balloon inflation on quantitative
analysis performed by the core laboratory. Routine use of
intravascular ultrasound probably would have been helpful in
ensuring optimal stent deployment in the present study.
Conclusions. In this multicenter registry with broad patient
and lesion inclusion criteria, the NIR stent proved highly
efficacious in the treatment of complex, obstructive coronary
artery disease. Because of its advanced stent design, the NIR
stent appears particularly suitable for implantation in complex
and difficult to reach lesions. A prospective, consecutive case
registry assessing late angiographic results and a multicenter,
randomized trial comparing the NIR stent with other currently
available stents are in progress. Thus, NIR stent implantation
is an effective means of treating patients with symptomatic
coronary artery disease and may be particularly useful in
patients with unfavorable lesions for percutaneous coronary
intervention.
Appendix
Participating Institutions and Investigators for the
FINESS Trial*
Canada: R. Bonan,* L. Bilodeau, Institute de Cardiologie de Montreal,
Montreal, Quebec (10); I. M. Penn,* C. E. Buller, D. R. Ricci, Vancouver General
Hospital, Vancouver, British Columbia (11). France: M. C. Morice,* P. Dumas, G.
Karrillon, T. Lefevre, Y. Louvari, Institut Cardiovasculaire Paris Sud, Antony (29);
J. Marco,* B. Cassagneau, Clinique Pasteur, Toulouse (21); J. L. Guermonprez,*
S. Makowski, J. Y. Pagny, Hopital Broussais, Paris (25). Germany: R. Erbel,* M.
Haude, University Hospital, Essen (16). Israel: Y. Almagor,* J. Balkin, S. Feld, M.
Klutstein, D. Rosenmann, D. Tzivoni, Shaare Zedek Medical Center, Jerusalem
(31). Italy: A. Colombo,* C. Di Mario, Centro Cuore Columbus, Milan (26). The
Netherlands: F. Kiemeneij,* G. J. Laarman, OLVG, Amsterdam (31); P. W.
Serruys,* J. Hamburger, Thoraxcenter, Rotterdam (30). Spain: C. Macaya,* A.
Fernandez-Ortiz, Hospital Clinico, Madrid (25).
*Principal investigator; numbers in parentheses are number of patients
enrolled at each site.
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